Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Serum uric acid and gout: from the past to molecular biology.

Punzi L, So A.

Curr Med Res Opin. 2013 Apr;29 Suppl 3:3-8. doi: 10.1185/03007995.2013.790800. Review.

PMID:
23621555
2.

An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.

PMID:
21654265
3.

Beyond gout: uric acid and cardiovascular diseases.

Agabiti-Rosei E, Grassi G.

Curr Med Res Opin. 2013 Apr;29 Suppl 3:33-9. doi: 10.1185/03007995.2013.790804. Epub 2013 Apr 24. Review.

PMID:
23611366
4.

Serum uric acid and cardio-renal diseases.

Ruilope LM, Pontremoli R.

Curr Med Res Opin. 2013 Apr;29 Suppl 3:25-31. doi: 10.1185/03007995.2013.790803. Review.

PMID:
23621557
5.

Febuxostat efficacy in allopurinol-resistant tophaceous gout.

Uh M, Reid G.

J Clin Rheumatol. 2011 Jun;17(4):204-6. doi: 10.1097/RHU.0b013e31821c0cae.

PMID:
21617552
7.
8.

Serum uric acid and metabolic risk.

Richette P, Perez-Ruiz F.

Curr Med Res Opin. 2013 Apr;29 Suppl 3:9-15. doi: 10.1185/03007995.2013.790801. Epub 2013 Apr 24. Review.

PMID:
23611367
9.

How to manage patients with gout.

Bardin T, Desideri G.

Curr Med Res Opin. 2013 Apr;29 Suppl 3:17-24. doi: 10.1185/03007995.2013.790802. Review.

PMID:
23621556
10.

Update on emerging urate-lowering therapies.

Chohan S, Becker MA.

Curr Opin Rheumatol. 2009 Mar;21(2):143-9. doi: 10.1097/BOR.0b013e328325bd94. Review. Erratum in: Curr Opin Rheumatol. 2010 Jan;22(1):106.

PMID:
19339925
11.

[Contribution of the CoLaus study to decipher the determinants of serum uric acid].

Bochud M, Vollenweider P, Waeber G.

Rev Med Suisse. 2011 Nov 2;7(315):2142, 2144-5. French.

PMID:
22187784
12.
13.

Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.

Bruce SP.

Ann Pharmacother. 2006 Dec;40(12):2187-94. Epub 2006 Nov 28. Review.

PMID:
17132810
14.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

15.

Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S50-6. doi: 10.1097/RHU.0b013e31822541d0.

PMID:
21654270
16.

Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.

Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L.

J Rheumatol. 2011 Jul;38(7):1385-9. doi: 10.3899/jrheum.101156. Epub 2011 May 15.

PMID:
21572152
17.

The kidney in hyperuricemia and gout.

Mount DB.

Curr Opin Nephrol Hypertens. 2013 Mar;22(2):216-23. doi: 10.1097/MNH.0b013e32835ddad2. Review.

PMID:
23318701
18.

Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.

Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, Luo T, Liu L, Chen S, Li Q.

Clin Ther. 2013 Feb;35(2):180-9. doi: 10.1016/j.clinthera.2012.12.011. Epub 2013 Jan 16. Review.

PMID:
23332451
19.

Safety of urate-lowering therapies: managing the risks to gain the benefits.

Keenan RT.

Rheum Dis Clin North Am. 2012 Nov;38(4):663-80. doi: 10.1016/j.rdc.2012.08.008. Epub 2012 Sep 7. Review.

PMID:
23137576
20.

Serum uric acid in 23,923 men and gout in a subsample of 4257 men in France.

Zalokar J, Lellouch J, Claude JR, Kuntz D.

J Chronic Dis. 1972 May;25(5):305-12. No abstract available.

PMID:
4639928

Supplemental Content

Support Center